Key facts
- Exthymic’s last known valuation is $30.3M (May 2024).
- It has raised $10.3M across 1 recorded rounds; the latest was Early Stage VC ($10.2M) in Apr 2024.
- Notable investors include CONNECT (San Diego), Dimension (United States), Alix Ventures, KdT Ventures, Phase Two Ventures.
- Exthymic has filed 1 Form D with the SEC, most recently May 2024 ($10.2M sold to 8 investors).
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Exthymic
Create free account
No card required
Funding rounds
1 roundsAbout Exthymic
Operator of a biotechnology company intended to focus on democratizing access to autologous cell therapies through point-of-care manufacturing. The company is currently operating in Stealth mode.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Website
- exthymic.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Exthymic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Exthymic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Exthymic in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.